This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CHO cells | |
|---|---|
| Name | CHO cells |
| Species | Cricetulus griseus |
| Cell type | epithelial-like |
| First isolation | 1957 |
| Uses | recombinant protein production, monoclonal antibody manufacture |
CHO cells
Chinese hamster ovary (CHO) cell derivatives constitute a widely used mammalian cell line family derived from the ovary of the Cricetulus griseus laboratory specimen first isolated in the mid-20th century. These epithelial-like lines underpin large parts of modern biopharmaceutical production, enabling expression systems that bridge classical genetics experiments, industrial biotechnology processes, and regulatory frameworks governed by agencies such as the Food and Drug Administration and the European Medicines Agency. CHO derivatives are foundational in workflows connecting academic laboratories at institutions like Cold Spring Harbor Laboratory and corporate research at firms such as Genentech and Amgen.
CHO derivatives trace to a 1957 isolation during an era when figures like James Watson and Francis Crick shaped molecular biology, and institutions such as the National Institutes of Health funded mammalian cell culture exploration. Early adoption in pharmaceutical laboratories at companies including Eli Lilly and Merck & Co. followed demonstration of robust growth in adherent culture media originally influenced by methods from labs at Rockefeller University and protocols developed by researchers associated with the Howard Hughes Medical Institute. During the 1980s and 1990s, biotechnology pioneers at Genentech and regulatory precedent set by approvals such as the first recombinant therapeutic licensed by the Food and Drug Administration accelerated CHO use for recombinant proteins and monoclonal antibodies.
CHO derivatives are derived from the ovary tissue of the Cricetulus griseus specimen and retain mammalian post-translational machinery including N-linked and O-linked glycosylation pathways influenced by enzymes encoded in loci studied in comparative work with species like Mus musculus and Homo sapiens. Their karyotype displays structural rearrangements and aneuploidy analogous to observations reported in cytogenetic surveys at centers such as St. Jude Children's Research Hospital, and their metabolic profile (glucose consumption, lactate production, glutamine utilization) is frequently optimized using strategies developed in collaboration with industrial partners like Baxter International and academic groups at Massachusetts Institute of Technology. CHO cells tolerate suspension culture and serum-free media, properties evaluated alongside other lines such as HEK 293 and Vero cells in comparative studies at laboratories including Ludwig Institute for Cancer Research.
Stable expression in CHO derivatives relies on vector systems and selection markers pioneered through work at institutions such as Stanford University and companies like Novartis. Techniques including dihydrofolate reductase (DHFR) amplification, methotrexate selection, and glutamine synthetase (GS) systems were optimized by teams at Biogen and academic groups at University of California, Berkeley. Contemporary genome editing approaches using CRISPR-Cas9 and zinc finger nucleases draw on foundational discoveries from laboratories led by figures like Jennifer Doudna and Feng Zhang. Cell banking strategies (master cell bank, working cell bank) align with regulatory expectations articulated by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and implemented in manufacturing facilities at corporations such as Pfizer.
CHO derivatives produce a majority of licensed recombinant therapeutic proteins and monoclonal antibodies, contributing to products from companies including Roche, Janssen Pharmaceuticals, and AbbVie. They are used to express enzymes, hormones, fusion proteins, and complex glycoproteins for indications managed in clinical settings overseen by organizations such as the World Health Organization and national regulators including the European Medicines Agency. CHO-derived biologics have facilitated therapies exemplified by blockbuster drugs developed by Amgen and Regeneron Pharmaceuticals, and underpin research collaborations across academic medical centers like Johns Hopkins University.
Standard culture of CHO derivatives employs formulations of chemically defined, serum-free media developed in collaboration with suppliers such as Thermo Fisher Scientific and GE Healthcare Life Sciences, and uses bioreactors designed by engineering firms like Sartorius and Eppendorf. Process parameters (dissolved oxygen, pH, shear stress) are controlled following engineering practices established at technical institutions including Massachusetts Institute of Technology and ETH Zurich. Fed-batch, perfusion, and continuous culture modes are selected based on productivity targets studied in pilot plants affiliated with companies such as Biocon and guidelines from the International Society for Pharmaceutical Engineering.
Manufacture using CHO derivatives is conducted under good manufacturing practice (GMP) frameworks enforced by agencies including the Food and Drug Administration and the European Medicines Agency, with quality oversight guided by standards from the United States Pharmacopeia and the International Organization for Standardization. Viral clearance, adventitious agent testing, and characterization assays draw on methods standardized at public health agencies like the Centers for Disease Control and Prevention and collaborative consortia involving World Health Organization expert committees. Regulatory filings for CHO-derived biologics reference assays for host cell protein, DNA content, and glycosylation profiles comparable to expectations set in guidances from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
CHO derivatives have limitations including non-human glycoforms and potential for product heterogeneity, challenges investigated in comparative projects at institutions such as Cambridge University and biotechnology firms like Celltrion. Alternatives explored include human-derived lines such as HEK 293, immortalized lines like PER.C6, and non-mammalian platforms (yeast strains used by companies like Novozymes and insect cell systems developed with technologies from Baculovirus research), as well as emerging cell-free expression systems commercialized by startups supported by incubators such as Y Combinator. Trade-offs among yield, post-translational fidelity, and regulatory precedent continue to drive diversification of host platforms across academic and industrial partnerships including collaborations with University of Pennsylvania and Imperial College London.
Category:Cell lines